Miragen reports promising results in ongoing trials of lymphoma drug

BOULDER — Miragen Therapeutics Inc. (Nasdaq: MGEN), a biopharmaceutical company based in Boulder, on Monday released promising interim results from an ongoing clinical trial of its drug MRG-106 on patients with mycosis fungoides, a rare type of lymphoma that affects the skin.

The data were presented at the American Society of Clinical Oncology annual meeting in Chicago.

The Phase 1 trial consists of two parts. In the first part, subjects were injected with MRG-106 directly into a specific lesion. The second part employed a dose-escalation that was injected subcutaneously or intravenously.

SPONSORED CONTENT

The many benefits of simple, coordinated healthcare

Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.

Eighteen of 19 subjects, or about 95 percent, regardless of how the drug was administered, showed improvement of varying degrees in either the individual lesion or total skin disease. One patient was withdrawn from the trial due to disease progression.

“We believe the enduring responses seen in this Phase 1 clinical trial of MRG-106 show potential for subjects with MF and other cancers where microRNA-155 is found at abnormally high levels,” said Dr. Paul Rubin, Miragen’s executive vice president of research and development. “While preliminary, the improvements appear to correlate with time on MRG-106 treatment, and the results’ trends suggest that longer duration of treatment could result in greater efficacy.”